Hemodialysis
Can omega-3s reduce cardiovascular events during hemodialysis?
Recent syntheses report promising cardiovascular findings in hemodialysis. A 2026 review cautions that much of the evidence comes from a single large trial.
Updated September 24, 2026 · Editorial attribution: PV Griscom, M.Sc. · Independent clinical review pending
The question behind the headline
People undergoing hemodialysis; cardiovascular mortality, heart attack and vascular access events.
What the finding does—and doesn’t—tell us
Results cannot be transferred to everyone with kidney disease. The review did not find an all-cause mortality benefit.
Read the underlying research.
Selected sources, not an exhaustive reference list. Research record or abstract screening only; full-text efficacy appraisal is pending. Source publication dates may precede this page’s update date.
Three questions to take forward
- Was the study population similar to the person or situation I have in mind?
- Did it measure an outcome people feel or experience, or only a laboratory marker?
- How do formulation, usual care, absolute benefit and adverse effects change the interpretation?
Study doses describe experiments; they are not personal dosing advice. Explore safety and limitations ↗